The research interests of our laboratory focus on the translational approach to investigate the mechanisms and discover new therapies for arrhythmias. We bridge the clinical and basic research units to work out the solution by the multidisciplinary collaboration. Several active fields of interests are the creation of biological pacemakers by direct reprogramming for cardiac conduction diseases; translational approaches to study genetics and mechanisms of arrhythmias; artificial intelligence (A.I.) to screen, prevent, and treat arrhythmias. The delivery of the transcription factor (TBX18) reprograms quiescent ventricular cardiomyocytes into beating pacemaker cells. Based on this interesting finding, we have further developed the innovative methods utilizing biomaterials and small molecules to create pacemaker cells in an efficient way. The biological pacemaker cells not only could be used as the alternative to the electronic device, but also applied as an in-vitro engineered cell or tissue model. Clinical genetics screening in the patients with arrhythmias revealed several potential pathogenetic genes for cardiac conduction diseases and arrhythmias. These have been undergoing validation by the arrhythmia models of transgenic mice and human induced pluripotent stem cell-derived cardiomyocytes. To catch up with future trend of biomedical analysis, we use A.I. to explore the clinical databases of arrhythmias including ECGs, genes, and biomarkers. We have come up with several A.I. models to diagnose arrhythmias, rare diseases, and non-invasive monitoring of cardiac phenotypes.